Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Antony Loebel

Showing results (1-10 of 128) with videos related to

Pageof 13
Sort By:
Bjpsych Bulletin|January 13, 2016
Lurasidone: a novel antipsychotic agent for the treatment of schizophrenia and bipolar depressionAntony Loebel, Leslie Citrome
CNS Spectrums|April 30, 2004
Improvement in prosocial functioning after a switch to ziprasidone treatmentAntony Loebel, Cynthia Siu, Steven Romano
Schizophrenia Research|May 7, 2018
Identifying the genetic risk factors for treatment response to lurasidone by genome-wide association study: A meta-analysis of samples from three independent clinical trialsJiang Li, Antony Loebel, Herbert Y Meltzer
Journal of the American Academy of Child and Adolescent Psychiatry|May 1, 2018
Clinical Relevance Versus Statistical Significance: DelBello and Colleagues Respond to EditorialMelissa P DelBello, Robert Goldman, Antony Loebel
CNS Drugs|September 14, 2007
Ziprasidone for the treatment of acute manic or mixed episodes associated with bipolar disorderLewis Warrington, Ilise Lombardo, Antony Loebel, et al.
Journal of Psychiatric Research|April 19, 2016
Lurasidone adjunctive with lithium or valproate for bipolar depression: A placebo-controlled trial utilizing prospective and retrospective enrolment cohortsTrisha Suppes, Hans Kroger, Andrei Pikalov, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|May 25, 2006
Electrocardiographic changes with ziprasidoneAntony Loebel, Jeffrey Miceli, Phillip Chappell, et al.
Current Medical Research and Opinion|January 19, 2017
Real-world adherence assessment of lurasidone and other oral atypical antipsychotics among patients with schizophrenia: an administrative claims analysisKrithika Rajagopalan, Sally Wade, Nicole Meyer, et al.
The Journal of Neuropsychiatry and Clinical Neurosciences|March 10, 2006
Neuropsychological normalization with long-term atypical antipsychotic treatment: results of a six-month randomized, double-blind comparison of ziprasidone vs. olanzapinePhilip D Harvey, Christopher R Bowie, Antony Loebel
Journal of Affective Disorders|November 20, 2013
Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmedLeslie Citrome, Terence A Ketter, Josephine Cucchiaro, et al.
Pageof 13

Showing results (1-10 of 128) with videos related to

Sort By:
Pageof 13
Bjpsych Bulletin|January 13, 2016
Lurasidone: a novel antipsychotic agent for the treatment of schizophrenia and bipolar depressionAntony Loebel, Leslie Citrome
CNS Spectrums|April 30, 2004
Improvement in prosocial functioning after a switch to ziprasidone treatmentAntony Loebel, Cynthia Siu, Steven Romano
Schizophrenia Research|May 7, 2018
Identifying the genetic risk factors for treatment response to lurasidone by genome-wide association study: A meta-analysis of samples from three independent clinical trialsJiang Li, Antony Loebel, Herbert Y Meltzer
Journal of the American Academy of Child and Adolescent Psychiatry|May 1, 2018
Clinical Relevance Versus Statistical Significance: DelBello and Colleagues Respond to EditorialMelissa P DelBello, Robert Goldman, Antony Loebel
CNS Drugs|September 14, 2007
Ziprasidone for the treatment of acute manic or mixed episodes associated with bipolar disorderLewis Warrington, Ilise Lombardo, Antony Loebel, et al.
Journal of Psychiatric Research|April 19, 2016
Lurasidone adjunctive with lithium or valproate for bipolar depression: A placebo-controlled trial utilizing prospective and retrospective enrolment cohortsTrisha Suppes, Hans Kroger, Andrei Pikalov, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|May 25, 2006
Electrocardiographic changes with ziprasidoneAntony Loebel, Jeffrey Miceli, Phillip Chappell, et al.
Current Medical Research and Opinion|January 19, 2017
Real-world adherence assessment of lurasidone and other oral atypical antipsychotics among patients with schizophrenia: an administrative claims analysisKrithika Rajagopalan, Sally Wade, Nicole Meyer, et al.
The Journal of Neuropsychiatry and Clinical Neurosciences|March 10, 2006
Neuropsychological normalization with long-term atypical antipsychotic treatment: results of a six-month randomized, double-blind comparison of ziprasidone vs. olanzapinePhilip D Harvey, Christopher R Bowie, Antony Loebel
Journal of Affective Disorders|November 20, 2013
Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmedLeslie Citrome, Terence A Ketter, Josephine Cucchiaro, et al.
Pageof 13